This meta-analysis provides robust evidence that bariatric metabolic surgery significantly reduces both major adverse cardiovascular events (MACE) and all-cause mortality compared to glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with obesity. Here, GLP1R is linked to obesity disorder.